[1] |
SIEGEL R, MA J M, ZOU Z H, et al. Cancer statistics, 2014[J]. CA A Cancer J Clin, 2014, 64(1): 9-29.
doi: 10.3322/caac.v64.1
|
[2] |
ZENG H M, RAN X H, AN L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6(12): e877-e887.
doi: 10.1016/S2468-2667(21)00157-2
pmid: 34838194
|
[3] |
OUDKERK M, LIU S Y, HEUVELMANS M A, et al. Lung cancer LDCT screening and mortality reduction-evidence, pitfalls and future perspectives[J]. Nat Rev Clin Oncol, 2021, 18(3): 135-151.
|
[4] |
MURPHY S J, AUBRY M C, HARRIS F R, et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small cell lung cancer[J]. J Clin Oncol, 2014, 32(36): 4050-4058.
doi: 10.1200/JCO.2014.56.7644
|
[5] |
CHANG Y L, WU C T, LIN S C, et al. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers[J]. Clin Cancer Res, 2007, 13(1): 52-58.
doi: 10.1158/1078-0432.CCR-06-1743
|
[6] |
BATTAFARANO R J, MEYERS B F, GUTHRIE T J, et al. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival[J]. Ann Thorac Surg, 2002, 74(4): 988-993;discussion 993-994.
doi: 10.1016/s0003-4975(02)03878-x
pmid: 12400733
|
[7] |
ZUIN A, ANDRIOLO L G, MARULLI G, et al. Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer?[J]. Eur J Cardiothorac Surg, 2013, 44(2): e120-e125;discussione125.
doi: 10.1093/ejcts/ezt219
|
[8] |
STELLA F, LUCIANO G, DELL’AMORE A, et al. Pulmonary metastases from NSCLC and MPLC (multiple primary lung cancers): management and outcome in a single centre experience[J]. Heart Lung Circ, 2016, 25(2): 191-195.
doi: 10.1016/j.hlc.2015.07.016
pmid: 26525847
|
[9] |
MASCALCHI M, COMIN C E, BERTELLI E, et al. Screen-detected multiple primary lung cancers in the ITALUNG trial[J]. J Thorac Dis, 2018, 10(2): 1058-1066.
doi: 10.21037/jtd.2018.01.95
pmid: 29607181
|
[10] |
ZHAO L S, LIU C Y, XIE G Y, et al. Multiple primary lung cancers: a new challenge in the era of precision medicine[J]. Cancer Manag Res, 2020, 12: 10361-10374.
doi: 10.2147/CMAR.S268081
pmid: 33116891
|
[11] |
BOYLE J M, TANDBERG D J, CHINO J P, et al. Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis[J]. Cancer, 2015, 121(4): 598-604.
doi: 10.1002/cncr.29095
pmid: 25283893
|
[12] |
HOWINGTON J A, BLUM M G, CHANG A C, et al. Treatment of stage Ⅰ and Ⅱ non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e278S-e313S.
doi: 10.1378/chest.12-2359
|
[13] |
WALLER D A. Surgical management of lung cancer with multiple lesions: implication of the new recommendations of the 8th edition of the TNM classification for lung cancer[J]. J Thorac Dis, 2018, 10(Suppl 22): S2686-S2691.
doi: 10.21037/jtd
|
[14] |
HAMAJI M, ALI S O, BURT B M. A meta-analysis of resected metachronous second non-small cell lung cancer[J]. Ann Thorac Surg, 2015, 99(4): 1470-1478.
doi: 10.1016/j.athoracsur.2014.11.033
pmid: 25725930
|
[15] |
DALWADI S M, SZEJA S S, BERNICKER E H, et al. Practice patterns and outcomes in elderly stage Ⅰ non-small-cell lung cancer: a 2004 to 2012 SEER analysis[J]. Clin Lung Cancer, 2018, 19(2): e269-e276.
doi: 10.1016/j.cllc.2017.11.004
|
[16] |
DETTERBECK F C, BOFFA D J, KIM A W, et al. The Eighth Edition Lung Cancer Stage Classification[J]. Chest, 2017, 151(1): 193-203.
doi: S0012-3692(16)60780-8
pmid: 27780786
|
[17] |
VIDETIC G M, PAULUS R, SINGH A K, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 103(5): 1077-1084.
doi: 10.1016/j.ijrobp.2018.11.051
|
[18] |
CHI A, WEN S J, LIAO Z X, et al. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer[J]. Biomed Res Int, 2013, 2013: 391021.
|
[19] |
Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0[R]. Bethesda: NIH, 2017.
|
[20] |
SHIN J Y, YOON J K, MARWAHA G. Progress in the treatment and outcomes for early-stage non-small cell lung cancer[J]. Lung, 2018, 196(3): 351-358.
doi: 10.1007/s00408-018-0110-1
pmid: 29550987
|
[21] |
TURNER K, BROWNSTEIN N C, THOMPSON Z, et al. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy[J]. Radiother Oncol, 2022, 167: 116-121.
doi: 10.1016/j.radonc.2021.12.021
|
[22] |
GULSTENE S, RUWANPURA T, PALMA D, et al. Stereotactic ablative radiotherapy in the treatment of early-stage lung cancer-A done deal?[J]. Clin Oncol (R Coll Radiol), 2022, 34(11): 733-740.
doi: 10.1016/j.clon.2022.08.027
|
[23] |
CHANG J Y, SENAN S, PAUL M A, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6): 630-637.
doi: 10.1016/S1470-2045(15)70168-3
|
[24] |
RAJU S C, PETERS G W, DECKER R H, et al. Clinical outcomes and safety profile in the treatment of synchronous nonmetastatic lung tumors with stereotactic body radiation therapy[J]. Pract Radiat Oncol, 2022, 12(2): e110-e116.
doi: 10.1016/j.prro.2021.11.006
|
[25] |
STEBER C R, HUGHES R T, SOIKE M H, et al. Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer[J]. Acta Oncol, 2021, 60(5): 605-612.
doi: 10.1080/0284186X.2021.1892182
|
[26] |
NIKITAS J, DEWEES T, REHMAN S, et al. Stereotactic body radiotherapy for early-stage multiple primary lung cancers[J]. Clin Lung Cancer, 2019, 20(2): 107-116.
doi: S1525-7304(18)30294-8
pmid: 30477740
|
[27] |
VERSTEGEN N E, LAGERWAARD F J, HASHEMI S M, et al. Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy[J]. J Thorac Oncol, 2015, 10(8): 1195-1200.
doi: 10.1097/JTO.0000000000000576
pmid: 26200274
|
[28] |
MIYAZAKI T, YAMAZAKI T, SATO S, et al. Surgery or stereotactic body radiotherapy for metachronous primary lung cancer? a propensity score matching analysis[J]. Gen Thorac Cardiovasc Surg, 2020, 68(11): 1305-1311.
doi: 10.1007/s11748-020-01394-3
|